e-therapeutics (ETX) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock ETX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 ...July 11, 2025 | morningstar.comMe-therapeutics plc: e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical DataJuly 10, 2025 | finanznachrichten.dee-therapeutics plc: e-therapeutics Presents New Data Supporting ETX-312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASHMay 7, 2025 | finanznachrichten.dee-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASHMay 7, 2025 | finance.yahoo.comEnsem Therapeutics Announces U.S. FDA IND Clearance to Initiate Clinical Development of ETX-636April 22, 2025 | tmcnet.comElicio Therapeutics stock slides on $10M securities offeringJanuary 30, 2025 | msn.comEnsem Therapeutics Announces Presentation at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | businesswire.comEnsem Therapeutics To Present Preclinical Data for Potential Best-in-Class Oral CDK2 Inhibitor at San Antonio Breast Cancer SymposiumDecember 10, 2024 | finance.yahoo.comAN2 Therapeutics to Meet With FDA on Epetraborole Development PathNovember 13, 2024 | marketwatch.comPositive Outlook for Akero Therapeutics Driven by Efruxifermin’s Potential and Strategic Clinical ProgramsNovember 11, 2024 | markets.businessinsider.comRBC Capital Releases a Buy Rating on Edgewise Therapeutics (EWTX)November 8, 2024 | markets.businessinsider.comAquestive Therapeutics: Progress in Drug InnovationNovember 6, 2024 | markets.businessinsider.come-therapeutics Announces Business Updates and Interim ResultsOctober 31, 2024 | markets.businessinsider.comEvecxia Therapeutics Announces Successful Completion of Pre-IND Meeting with the FDA Regarding Development of EVX-101 For DepressionOctober 27, 2024 | businesswire.comIterum Therapeutics Shares Soar on FDA's Orlynvah ApprovalOctober 25, 2024 | marketwatch.comPerspective Therapeutics (CATX) Gets a Buy from OppenheimerOctober 22, 2024 | markets.businessinsider.comETXPF e-therapeutics plcOctober 19, 2024 | seekingalpha.comTruist Financial Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)September 18, 2024 | markets.businessinsider.comERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024May 14, 2024 | markets.businessinsider.come-therapeutics plc shares now trading on JP JenkinsMay 9, 2024 | markets.businessinsider.comE-therapeutics Share ChatApril 20, 2024 | lse.co.ukEliem Therapeutics to buy Tenet, announces $120 million private placementApril 11, 2024 | msn.comAquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024April 10, 2024 | seekingalpha.come-Therapeutics says company faces lack of interest as UK listingApril 10, 2024 | lse.co.uke-Therapeutics Shares Fall on London Delisting Plan; Mulls Move to New YorkApril 10, 2024 | marketwatch.com‘Lack of appetite’ in London drives another high-tech firm to NasdaqApril 10, 2024 | msn.comDrug discovery firm e-therapeutics to quit London Stock Exchange following £29m fundraiseApril 10, 2024 | msn.come-therapeutics (LON:ETX) Stock Passes Below 200 Day Moving Average of $12.11April 2, 2024 | marketbeat.comAquestive maps out FDA approval for sublingual anaphylaxis drugMarch 15, 2024 | msn.come-therapeutics (LON:ETX) Stock Price Crosses Below Two Hundred Day Moving Average of $12.41March 15, 2024 | marketbeat.come-therapeutics (LON:ETX) Shares Pass Below 200-Day Moving Average of $12.52March 7, 2024 | marketbeat.comWe're Hopeful That e-therapeutics (LON:ETX) Will Use Its Cash WiselyJanuary 3, 2024 | finance.yahoo.comMedical innovator e-therapeutics to stop trading on US-based marketDecember 27, 2023 | msn.comEdison issues update on e-therapeutics (ETX): More to come in RNAi therapy discoveryNovember 13, 2023 | markets.businessinsider.comEvecxia Therapeutics Strengthens Board of Directors With Appointments of Allan L. Shaw and Elliot EhrichOctober 30, 2023 | businesswire.comE-therapeutics bolsters generative AI integration and strategic...October 26, 2023 | proactiveinvestors.comU.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-TelangiectasiaSeptember 28, 2023 | benzinga.comQuince Therapeutics to Advance Study of EryDex as FDA Lifts Application HoldSeptember 28, 2023 | marketwatch.come-therapeutics appoints new CFOSeptember 20, 2023 | proactiveinvestors.comETX.L - e-Therapeutics plcJuly 13, 2023 | uk.finance.yahoo.comElicio Therapeutics Inc.June 8, 2023 | wsj.comAgeX Therapeutics Announces Appeal of NYSE American DeterminationMay 23, 2023 | businesswire.comRapid Dose Therapeutics Launches QuickStrip™ Dental Products in the Canadian MarketMay 10, 2023 | businesswire.comDelix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001May 10, 2023 | marketwatch.comAcute Renal Failure Therapeutics Market Located Worldwide Trends and Application – Baxter,Teva Pharmaceutical,PfizerMay 6, 2023 | marketwatch.comE-Therapeutics FY 2023 Pretax Loss Widened on Higher R&D CostsMay 4, 2023 | marketwatch.come-Therapeutics working to capitalise on AI "blindside"May 4, 2023 | finance.yahoo.comRelief Therapeutics Announces Results of Extraordinary General Meeting of ShareholdersApril 28, 2023 | markets.businessinsider.com8-K: Seres Therapeutics, Inc.April 27, 2023 | marketwatch.comAquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant(TM) (diazepam) Buccal Film to Additional Global MarketsMarch 30, 2023 | marketwatch.com Get e-therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ETX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ETX Media Mentions By Week ETX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ETX News Sentiment▼0.001.11▲Average Medical News Sentiment ETX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ETX Articles This Week▼00▲ETX Articles Average Week Get the Latest News and Ratings for ETX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for e-therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AVCT News BVXP News OBI News 4BB News SCLP News HVO News SBTX News FUM News SAR News AREC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:ETX) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding e-therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share e-therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
